Your browser doesn't support javascript.
loading
Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma / 대한내과학회지
Korean Journal of Medicine ; : 152-158, 2019.
Article in Korean | WPRIM | ID: wpr-759927
ABSTRACT
CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Organization and Administration / United States Food and Drug Administration / B-Lymphocytes / Receptors, Antigen / T-Lymphocytes / Biomarkers / Lymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse / Cell- and Tissue-Based Therapy / Korea Type of study: Prognostic study Limits: Humans Country/Region as subject: Asia Language: Korean Journal: Korean Journal of Medicine Year: 2019 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Organization and Administration / United States Food and Drug Administration / B-Lymphocytes / Receptors, Antigen / T-Lymphocytes / Biomarkers / Lymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse / Cell- and Tissue-Based Therapy / Korea Type of study: Prognostic study Limits: Humans Country/Region as subject: Asia Language: Korean Journal: Korean Journal of Medicine Year: 2019 Type: Article